Edition:
United Kingdom

Axovant Sciences Ltd (AXON.OQ)

AXON.OQ on NASDAQ Stock Exchange Global Select Market

5.46USD
12 Dec 2017
Change (% chg)

$0.19 (+3.61%)
Prev Close
$5.27
Open
$5.27
Day's High
$5.46
Day's Low
$5.27
Volume
234,286
Avg. Vol
396,166
52-wk High
$27.93
52-wk Low
$4.60

Chart for

About

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer's disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive,... (more)

Overall

Beta: --
Market Cap(Mil.): $758.06
Shares Outstanding(Mil.): 107.53
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

CORRECTED-BRIEF-Axovant Sciences Submitted Final Protocol With Statistical Analysis Plan To FDA For Dementia With Lewy Bodies Study

* AXOVANT SCIENCES - SUBMITTED FINAL PROTOCOL WITH STATISTICAL ANALYSIS PLAN TO FDA DESIGNATES UNIFIED PARKINSON DISEASE RATING SCALE - PART III AS PRIMARY EFFICACY ENDPOINT

07 Dec 2017

BRIEF-Axovant announces second fiscal quarter results

* Axovant announces second fiscal quarter financial results and corporate updates

02 Nov 2017

Axovant to pull plug on Alzheimer's drug after key study fails

Drug developer Axovant Sciences Ltd said it would stop testing its lead drug in Alzheimer's after it failed to meet the main goals of a late-stage trial, underlining the challenges in developing treatments for the memory-robbing disease.

26 Sep 2017

UPDATE 3-Axovant to pull plug on Alzheimer's drug after key study fails

* Shares hit record low (Adds details, conference call and analyst comments; updates shares)

26 Sep 2017

BRIEF-Axovant announces negative topline results of intepirdine phase 3 mindset trial in Alzheimer's disease

* At 24 weeks, patients treated with 35 mg of intepirdine did not experience improvement in cognition

26 Sep 2017

Axovant's Alzheimer's drug fails late-stage trial

Sept 26 Axovant Sciences Ltd said on Tuesday its experimental drug targeting Alzheimer's patients failed to meet the main goals in a late-stage trial.

26 Sep 2017

Earnings vs. Estimates